Skip to main content

Table 2 Most frequent (≥10% of patients) treatment-emergent adverse events of any grade in the safety population

From: Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

TEAE Overall (N = 97)
Any grade, n (%) Grade ≥3, n (%)
Asthenia/fatigue 56 (57.7) 8 (8.2)
Nausea 41 (42.3) 1 (1.0)
Anemiaa 35 (36.1) 20 (20.6)
Decreased appetite 28 (28.9) 2 (2.1)
Thrombocytopeniab 22 (22.7) 11 (11.3)
Vomiting 22 (22.7) 1 (1.0)
Blood creatinine increased 21 (21.6) 1 (1.0)
Constipation 21 (21.6) 3 (3.1)
ALT/AST increased 17 (17.5) 5 (5.2)
Dysgeusia 16 (16.5) 0
Dyspnea 13 (13.4) 3 (3.1)
Weight decreased 13 (13.4) 0
Diarrhea 12 (12.4) 1 (1.0)
Urinary tract infection 12 (12.4) 4 (4.1)
Abdominal pain 11 (11.3) 1 (1.0)
Hypophosphatemia 10 (10.3) 5 (5.2)
Dehydration 10 (10.3) 2 (2.1)
Insomnia 10 (10.3) 0
Pyrexia 10 (10.3) 1 (1.0)
  1. ALT alanine aminotransferase; AST aspartate aminotransferase; TEAE treatment-emergent adverse event.
  2. Visit cutoff date: February 20, 2020.
  3. a Combined term for anemia or decreased hemoglobin.
  4. b Combined term for thrombocytopenia or decreased platelets.